ST104P, an anti-angiogenic agent

Details ST104P, an anti-angiogenic agent ST104P, an anti-angiogenic agent

2007-09-25

2007-09-25

Spivack, Phyllis (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

C-o-group doai

Reexamination Certificate

active

10865480

ABSTRACT:
The anti-angiogenic functions of a polysulfated, cyclic compound, ST104P, were investigated. ST104P exhibited excellent water solubility and low cytotoxicity to endothelial cells. ST104P potently inhibited the secretion of matrix metalloproteinase (MMPs) by endothelial cells. Moreover, ST104 also perturbed the migration and tube formation of endothelial cells. Application of ST104P abolished the neovascularization in chicken choroiallantoic membrane (CAM) in a dose-dependent manner. Besides, repeated administration of ST104P into Lewis lung carcinoma resulted in delayed tumor growth and prolonged the life span of tumor-bearing mice. These results indicated that ST104P inhibited angiogenesis and may hold promises for treatment of cancer and diseases or conditions caused by excessive angiogenesis.

REFERENCES:
patent: 5166173 (1992-11-01), Hwang et al.
patent: 5196452 (1993-03-01), Hwang et al.
patent: 5312837 (1994-05-01), Hwang et al.
patent: 5409959 (1995-04-01), Hwang et al.
patent: 5441983 (1995-08-01), Hwang et al.
patent: 6518298 (2003-02-01), Green et al.
Gutman et al. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res., 1996, vol. 16, pp. 3673-3677.
Johnson et al. Relationships between drug activity in NCI preclincal in vitro and in vivo models and early clincal trials. British J. of Cancer, 2001, 84(10):1424-1431.
Vertun-Baranowska et al. Pulmonary embolism in malignancy of the lung: a retrospective clinical evaluation and pathomorphologic personal material. Pneumonol. Alergol. Pol., 1996, vol. 64, pp. 392-402 (Abstract only).
Bo-Long Poh and Chooi Seng Lim “Complexations of Amines With Water-Soluble Cyclotetrachromotropyleve”, Tetrahedron vol. 46, No. 10, (1990), p. 3651-3658.
Bo-Long Poh et al, “Complexations of Metal Cations With Cycltettachroma-Pylone in Water and Methanal”, Tetrahedron 46, No. 12 (1990), p. 4379-4386.
Smith et al, “Changes in the Antiangiogenic Properties of Articular Cartilage in Osteoarthritis”, J Orhop Sci (2003), 8-849-857.
Hans-Peter Hammes, “Ocular Complications in Diabetes” [Disclosures] 59th Annual Scientific Session of ADA, San Diego, CA 1999.
Lee M. Jampol, “Advances in the Treatment Of Age-Related Macular Degeneration and Other Retinal Disorders” (Disclosures), American Academy Opthalmalogy 2002, Meeting, Florida.
Tamara Saiam Housman et al, “Low-Dose Thalidomide Therapy for Refractory Cutaneous Lesions Of Lupus Ergohematosus”, Arch Dermatol vol. 139 (2003), p. 50-54.
A, Ossandon et al, “Thalidomide: Focus On Its Employment In Yheumatologic Disease”, Clinical And Experimental RHeumotogy 2002; 20: 709-718.
Abdulah Alfadley et al, “Thalidomide for Treatment of Severe Generated Discoid Lupus Lesions In Two Patients With Systemic Lupus Erythematosus”, J. Am. Acad. Dermatol 2003; 48: 589-91.
Michael S. O'Reilly et al; “Endostatin: An Endogenous Inhibitor Of Angiogenesis and Tumor Growth”, Cell, 1997; 88: 277-285.
Bruce R. Zeteer; “Angiogenesis and Tumor Metastasis” Annu. Rev. Med. 1998; 49: 407-24.
Joen R. Sheu et al; “Effect of U-995, A Potent Shark Cartilage-Derived Angiogensis Inhibitor, On Anti-Angogenesis and Anit-Tumor Activities”; Anticancer Research 18: 4435-4442 (1998).
D. Kurosaka, et al, “Inhibition Of Arthritis By Systemic Administration Of Endostatin In Passive Murine Callagen Induced Arthritis”, Ann Rheum Dis 2003; 62: 677-679.
Percy F. Sumariwalla et al; The Angiogenesis Inhibitor Potease-Activated Kringles 1-5 Reduces the Severity of Murine Collagen Induced Arthritis; Arthritis Research and Therapy 2003 vol 5 (1): R32-R39.
Karens. Moulton et al; “Angrogenesis Inhibitors Endostatin or TNP-470 Reduce Intimal Neovascularization and Plaque Growth in Apolipo Protein E—Deficient Mice”; Circulation; 1998; 99: 1726-1732.
B. Ren et al; “Recombinant Human Endostatin Is Beneficial To Endothelial Cell Growth Exposed to Mildley Oxidized Love-Density Lipoproteins”; Methods Find Exp Clin Pharmacol 2002, 24(4): 195-199.
Chi-Chun Lai et al; “Suppression of Choroidal Neovascularization By Adeno-Associated Virus Vector Expressioning Angiostatin”; Investigative Ophthalmology & Visual Science, 2001; 42 (10): 2401-2407.
Michale S. O'Reilly et al; “Angiostatin: A Novel Angiogenesis Inhibitor That Mediates The Suppression of Metastases by a Lewis Lung Carcinoma”; Cell 1994; 79:315-328.

Affiliated with

Also associated with

Rating

ST104P, an anti-angiogenic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with ST104P, an anti-angiogenic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ST104P, an anti-angiogenic agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3767593